TY - JOUR
T1 - Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
AU - Ino, K.
AU - Yoshida, N.
AU - Kajiyama, H.
AU - Shibata, K.
AU - Yamamoto, E.
AU - Kidokoro, K.
AU - Takahashi, N.
AU - Terauchi, M.
AU - Nawa, A.
AU - Nomura, S.
AU - Nagasaka, T.
AU - Takikawa, O.
AU - Kikkawa, F.
N1 - Funding Information:
This work was supported by Grants-in-aid No. 15591742 (to KI) and No. 18591831 (to KI) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.
PY - 2006/12/4
Y1 - 2006/12/4
N2 - Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in endometrial cancer tissues (n=80) was immunohistochemically scored as four groups (IDO-, 1+, 2+, and 3+). The high IDO expression (IDO2+ or 3+) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade. Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P=0.002 and P=0.001, respectively) compared to patients with no or weak expression of IDO (IDO- or 1+). The 5-year PFS for IDO-/1+, 2+, and 3+ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n=64), the PFS for IDO2+/3+ was significantly poor (P=0.001) compared to that for IDO-/1+. On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P=0.020). These results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.
AB - Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolising enzyme inducing immune tolerance. The present study aimed to investigate IDO expression and its prognostic significance in endometrial cancer. Indoleamine 2,3-dioxygenase expression in endometrial cancer tissues (n=80) was immunohistochemically scored as four groups (IDO-, 1+, 2+, and 3+). The high IDO expression (IDO2+ or 3+) in tumour cells was found in 37 (46.3%) of the 80 cases, and was positively correlated with surgical stage, myometrial invasion, lymph-vascular space involvement, and lymph node metastasis, but not with the histological grade. Patients with high IDO expression had significantly impaired overall survival and progression-free survival (PFS) (P=0.002 and P=0.001, respectively) compared to patients with no or weak expression of IDO (IDO- or 1+). The 5-year PFS for IDO-/1+, 2+, and 3+ were 97.7, 72.9, and 36.4%, respectively. Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n=64), the PFS for IDO2+/3+ was significantly poor (P=0.001) compared to that for IDO-/1+. On multivariate analysis, IDO expression was an independent prognostic factor for PFS (P=0.020). These results indicated that the high IDO expression was involved in the progression of endometrial cancer and correlated with the impaired clinical outcome, suggesting that IDO is a novel and reliable prognostic indicator for endometrial cancer.
UR - http://www.scopus.com/inward/record.url?scp=33845246900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845246900&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6603477
DO - 10.1038/sj.bjc.6603477
M3 - Article
C2 - 17117179
AN - SCOPUS:33845246900
SN - 0007-0920
VL - 95
SP - 1555
EP - 1561
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 11
ER -